Skip NavigationSkip to Content
Return Return to Search Results

Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury

  1. Author:
    Hoshino, T.
    Nakamura, H.
    Okamoto, M.
    Kato, S.
    Araya, S.
    Nomiyama, K.
    Oizumi, K.
    Young, H. A.
    Aizawa, H.
    Yodoi, J.

  2. Author Address

    Kurume Univ, Sch Med, Dept Internal Med 1, 67 Asahimachi, Kurume, Fukuoka 8300011, Japan Kurume Univ, Sch Med, Dept Internal Med 1, Kurume, Fukuoka 8300011, Japan Kurume Univ, Dept Pathol, Kurume, Fukuoka 8300011, Japan Kyoto Univ, Inst Virus Res, Dept Biol Res, Kyoto 606, Japan NCI, Expt Immunol Lab, DBS, Frederick, MD 21701 USA Hoshino T Kurume Univ, Sch Med, Dept Internal Med 1, 67 Asahimachi, Kurume, Fukuoka 8300011, Japan
    1. Year: 2003
  2. Journal: American Journal of Respiratory and Critical Care Medicine
    1. 168
    2. 9
    3. Pages: 1075-1083
  4. Type of Article: Article
  1. Abstract:

    Thioredoxin (TRX) is a multifunctional redox (reduction/oxidation)-active protein that scavenges reactive oxygen species by itself or together with TRX-dependent peroxiredoxin. TRX also has chemo-taxis-modulating functions and suppresses leukocyte infiltration into sites of inflammation. Leukocyte infiltration and oxidative stress may be involved in the pathogenesis of several diseases, including interstitial lung diseases (ILD). We examined the effects of TRX in two mouse models of human ILD. Recently, we established a new mouse model for human ILD in which daily administration of proinflammatory cytokine interleukin (IL)-18 with IL-2 induces lethal lung injury accompanied by acute interstitial inflammatory responses. Administration of recombinant TRX suppressed IL-18/IL-2-induced interstitial infiltration of cells and prevented death and lung tissue damage. TRX- transgenic mice also showed resistance to lethal lung injury caused by IL-18/IL-2. Administration of bleomycin induces the infiltration of polymorphonuclear and mononuclear leukocytes in the pulmonary interstitium, followed by progressive fibrosis. Wild-type mice given recombinant TRX treatment and TRX- transgenic mice demonstrated a decrease in bleomycin-induced cellular infiltrates and fibrotic changes in the lung tissue. These results suggest that TRX modulates pulmonary inflammatory responses and acts to prevent lung injury. TRX may have clinical benefits in human ILD, including lung fibrosis, for which no effective therapeutic strategy currently exists.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel